{"nctId":"NCT03691779","briefTitle":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","startDateStruct":{"date":"2018-10-02","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":71,"armGroups":[{"label":"Part A: ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]},{"label":"Part B: ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous or heterozygous for F508del mutation (F/F or F/MF genotypes)\n* Forced expiratory volume in 1 second (FEV1) value â‰¥40% of predicted mean for age, sex, and height.\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status.\n* Solid organ or hematological transplantation.\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.13","spread":"1.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.281"}]}]}]},{"type":"PRIMARY","title":"Part A: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"0.366"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.297","spread":"0.173"}]}]}]},{"type":"PRIMARY","title":"Part A: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":"28.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":"13.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.12","spread":"2.93"}]}]}]},{"type":"PRIMARY","title":"Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Cmax of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.657"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.26","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"0.694"}]}]}]},{"type":"SECONDARY","title":"Part A: Ctrough of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"0.585"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.64","spread":"1.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.890","spread":"0.460"}]}]}]},{"type":"SECONDARY","title":"Part A: AUC0-24h of ELX Metabolite (M23-ELX) and TEZ Metabolite (M1-TEZ)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":"13.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":"30.4"}]}]}]},{"type":"SECONDARY","title":"Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)","description":"The AUC data was analyzed for up to 6 hours for IVA metabolite (M1-IVA). Therefore, AUC0-6h is reported for M1-IVA metabolite.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.41","spread":"3.06"}]}]}]},{"type":"SECONDARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With TEAEs and SAEs","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kg divided by squared height in meters (m\\^2).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in BMI For-Age Z-Score","description":"BMI was defined as weight in kg divided by squared height in meters (m\\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Weight","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Weight-for-age Z-Score","description":"The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Height","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Height-for-Age Z-Score","description":"The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale","description":"The study drug acceptability (participant reaction) was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). Number of participants with the indicated categorical response in the drug acceptability assessment were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Pulmonary Exacerbations Events","description":"Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. The total number of pulmonary exacerbations events across all participants were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Number of CF Related Hospitalizations","description":"The total number of CF related hospitalization events across all participants were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Ctrough of ELX, ELX Metabolite (M23-ELX), TEZ, TEZ Metabolite (M1-TEZ), IVA and IVA Metabolite (M1-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.69","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.41","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.57","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.12","spread":"1.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.455","spread":"0.681"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.851","spread":"0.489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.630"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)","description":"LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Cough","Headache","Pyrexia","Oropharyngeal pain","Nasal congestion"]}}}